Cargando…
Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab
PURPOSE: In a benchwork particle counting analytical evaluation, the number and type of particles in intravitreal injection formulations of three different agents against vascular endothelial growth factor were investigated. METHODS: Commercially available ready-to-use aflibercept and brolucizumab g...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Association for Research in Vision and Ophthalmology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375009/ https://www.ncbi.nlm.nih.gov/pubmed/34406342 http://dx.doi.org/10.1167/tvst.10.9.21 |
_version_ | 1783740235140562944 |
---|---|
author | Schargus, Marc Kopp, Katharina Tatjana Helbig, Constanze Frings, Andreas Winter, Gerhard |
author_facet | Schargus, Marc Kopp, Katharina Tatjana Helbig, Constanze Frings, Andreas Winter, Gerhard |
author_sort | Schargus, Marc |
collection | PubMed |
description | PURPOSE: In a benchwork particle counting analytical evaluation, the number and type of particles in intravitreal injection formulations of three different agents against vascular endothelial growth factor were investigated. METHODS: Commercially available ready-to-use aflibercept and brolucizumab glass syringes, vials containing bevacizumab (off-label use in ophthalmology), and repackaged ready-to-use plastic syringes containing bevacizumab were tested without filtration. Total visible, subvisible, and nanoparticles numbers and size distributions were quantified using light obscuration, flow imaging, resonant mass measurement (RMM), tunable resistive pulse sensing, and dynamic light scattering. RESULTS: Repackaged bevacizumab showed overall low particle numbers, aflibercept showed high numbers of micrometer sized particles but low nanoparticle numbers, brolucizumab showed low to moderate numbers of micrometer sized particles but high nanoparticle numbers. RMM measurements identified particles in the nanometer range as either proteinaceous or silicon oil; the nature of the other particles was not further evaluated. CONCLUSIONS: Repackaged bevacizumab shows no inferior particle quality compared to ready-to-use products. It is relevant to study nanoparticle load of the products as the micrometer-sized particle numbers do not in all cases correlate to nanoparticle counts. Particularly for the high concentration product Beovu (brolucizumab), high nanoparticle numbers were found despite low numbers of micrometer sized particles. Silicone oil droplets did not account for high particle numbers as the measured numbers were low. TRANSLATIONAL RELEVANCE: Different side effects are registered in different frequencies with different intravitreal anti-VEGF-drugs and syringes, which are applied by injection by small 30G needles through the sclera directly to the intravitreal cavity. The study of nanoparticles and silicone oil droplets may be able to contribute to narrowing down the causes. |
format | Online Article Text |
id | pubmed-8375009 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Association for Research in Vision and Ophthalmology |
record_format | MEDLINE/PubMed |
spelling | pubmed-83750092021-08-26 Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab Schargus, Marc Kopp, Katharina Tatjana Helbig, Constanze Frings, Andreas Winter, Gerhard Transl Vis Sci Technol Article PURPOSE: In a benchwork particle counting analytical evaluation, the number and type of particles in intravitreal injection formulations of three different agents against vascular endothelial growth factor were investigated. METHODS: Commercially available ready-to-use aflibercept and brolucizumab glass syringes, vials containing bevacizumab (off-label use in ophthalmology), and repackaged ready-to-use plastic syringes containing bevacizumab were tested without filtration. Total visible, subvisible, and nanoparticles numbers and size distributions were quantified using light obscuration, flow imaging, resonant mass measurement (RMM), tunable resistive pulse sensing, and dynamic light scattering. RESULTS: Repackaged bevacizumab showed overall low particle numbers, aflibercept showed high numbers of micrometer sized particles but low nanoparticle numbers, brolucizumab showed low to moderate numbers of micrometer sized particles but high nanoparticle numbers. RMM measurements identified particles in the nanometer range as either proteinaceous or silicon oil; the nature of the other particles was not further evaluated. CONCLUSIONS: Repackaged bevacizumab shows no inferior particle quality compared to ready-to-use products. It is relevant to study nanoparticle load of the products as the micrometer-sized particle numbers do not in all cases correlate to nanoparticle counts. Particularly for the high concentration product Beovu (brolucizumab), high nanoparticle numbers were found despite low numbers of micrometer sized particles. Silicone oil droplets did not account for high particle numbers as the measured numbers were low. TRANSLATIONAL RELEVANCE: Different side effects are registered in different frequencies with different intravitreal anti-VEGF-drugs and syringes, which are applied by injection by small 30G needles through the sclera directly to the intravitreal cavity. The study of nanoparticles and silicone oil droplets may be able to contribute to narrowing down the causes. The Association for Research in Vision and Ophthalmology 2021-08-18 /pmc/articles/PMC8375009/ /pubmed/34406342 http://dx.doi.org/10.1167/tvst.10.9.21 Text en Copyright 2021 The Authors https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License. |
spellingShingle | Article Schargus, Marc Kopp, Katharina Tatjana Helbig, Constanze Frings, Andreas Winter, Gerhard Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab |
title | Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab |
title_full | Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab |
title_fullStr | Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab |
title_full_unstemmed | Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab |
title_short | Comparison of Syringes With Intravitreal Anti-VEGF Drugs: Particle Burden and Protein Aggregates in Brolucizumab, Aflibercept and Bevacizumab |
title_sort | comparison of syringes with intravitreal anti-vegf drugs: particle burden and protein aggregates in brolucizumab, aflibercept and bevacizumab |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375009/ https://www.ncbi.nlm.nih.gov/pubmed/34406342 http://dx.doi.org/10.1167/tvst.10.9.21 |
work_keys_str_mv | AT schargusmarc comparisonofsyringeswithintravitrealantivegfdrugsparticleburdenandproteinaggregatesinbrolucizumabafliberceptandbevacizumab AT koppkatharinatatjana comparisonofsyringeswithintravitrealantivegfdrugsparticleburdenandproteinaggregatesinbrolucizumabafliberceptandbevacizumab AT helbigconstanze comparisonofsyringeswithintravitrealantivegfdrugsparticleburdenandproteinaggregatesinbrolucizumabafliberceptandbevacizumab AT fringsandreas comparisonofsyringeswithintravitrealantivegfdrugsparticleburdenandproteinaggregatesinbrolucizumabafliberceptandbevacizumab AT wintergerhard comparisonofsyringeswithintravitrealantivegfdrugsparticleburdenandproteinaggregatesinbrolucizumabafliberceptandbevacizumab |